Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06998108

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

A Multicenter, Randomized, Controlled, Double-blind Phase III Clinical Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant for the Treatment of HR+/HER2- Locally Advanced or Metastatic Breast Cancer in Patients With Disease Progression After Prior Endocrine Therapy

Sponsor: BeBetter Med Inc

Conditions HR+/HER2- Locally Advanced, Metastatic Breast Cancer

Interventions BEBT-209 Placebo capluses BEBT-209 capsules Fulvestrant Injection

Updated 2 times since 2025 Last updated: May 29, 2025 Started: Jun 9, 2022 Primary completion: Dec 31, 2025 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06998108, this PHASE3 trial focuses on HR+/HER2- Locally Advanced, Metastatic Breast Cancer and remains actively recruiting participants. Sponsored by BeBetter Med Inc, it has been updated 2 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

2 versions recorded

Jul 2025 — Present [monthly]

Recruiting PHASE3
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE3

First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeBetter Med Inc
Chinese Academy of Medical Sciences

Data source: BeBetter Med Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China